A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

PURPOSE: Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of the oral, first-in-class, glutaminase (GLS) inhibitor telaglenastat was conducted in treatment-refractory solid tumor patients to defin...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, James J., Telli, Melinda, Munster, Pamela, Voss, Martin H., Infante, Jeffrey R., DeMichele, Angela, Dunphy, Mark, Le, Mai H., Molineaux, Chris, Orford, Keith, Parlati, Frank, Whiting, Sam H., Bennett, Mark K., Tannir, Nizar M., Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401498/
https://www.ncbi.nlm.nih.gov/pubmed/34285061
http://dx.doi.org/10.1158/1078-0432.CCR-21-1204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401498/
https://www.ncbi.nlm.nih.gov/pubmed/34285061
http://dx.doi.org/10.1158/1078-0432.CCR-21-1204

Ejemplares similares